L04A immunosuppressive drug inmunosupresor 免疫抑制药 免疫抑制藥 L3
Source: Wikidata · CC0 1.0 Fuente: Wikidata · CC0 1.0 来源:维基数据 · CC0 1.0 來源:維基數據 · CC0 1.0
ATC level L3 · Search this class · Consumer categories
Child classes
L04AASelective immunosuppressants Selective immunosuppressants 选择性免疫抑制剂 選擇性免疫抑制劑L04ABTumor necrosis factor alpha (TNF-α) inhibitors Tumor necrosis factor alpha (TNF-α) inhibitors 肿瘤坏死因子α(TNF-α)抑制剂 腫瘤壞死因子α(TNF-α)抑制劑L04ACInterleukin inhibitors Interleukin inhibitors 白细胞介素抑制剂 白血球介素抑制劑L04ADcalcineurin inhibitor calcineurin inhibitor 钙调磷酸酶抑制剂 鈣調磷酸酶抑制劑L04AESphingosine 1-phosphate (S1P) receptor modulators Sphingosine 1-phosphate (S1P) receptor modulators Sphingosine 1-phosphate (S1P) receptor modulators Sphingosine 1-phosphate (S1P) receptor modulatorsL04AFJanus-associated kinase (JAK) inhibitors Janus-associated kinase (JAK) inhibitors Janus-associated kinase (JAK) inhibitors Janus-associated kinase (JAK) inhibitorsL04AGMonoclonal antibodies Monoclonal antibodies Monoclonal antibodies Monoclonal antibodiesL04AHMammalian target of rapamycin (mTOR) kinase inhibitors Mammalian target of rapamycin (mTOR) kinase inhibitors Mammalian target of rapamycin (mTOR) kinase inhibitors Mammalian target of rapamycin (mTOR) kinase inhibitorsL04AJComplement inhibitors Complement inhibitors Complement inhibitors Complement inhibitorsL04AKDihydroorotate dehydrogenase (DHODH) inhibitors Dihydroorotate dehydrogenase (DHODH) inhibitors Dihydroorotate dehydrogenase (DHODH) inhibitors Dihydroorotate dehydrogenase (DHODH) inhibitorsL04ALNeonatal fragment crystallizable receptor (FcRn) inhibitors Neonatal fragment crystallizable receptor (FcRn) inhibitors Neonatal fragment crystallizable receptor (FcRn) inhibitors Neonatal fragment crystallizable receptor (FcRn) inhibitorsL04AXOther immunosuppressants Other immunosuppressants 其它免疫抑制剂 其它免疫抑制劑
Active ingredients in this class
139 active ingredients 139 principios activos 139 个活性成分 139 個有效成分
The market codes after a status are the markets where that status is recorded (same codes as the product tables). An ingredient can be on sale in one market and withdrawn in another; that is a record fact, not a safety judgement.
A missing name is marked in its row only when it is the exception; when most names lack it, the list stays unmarked.
- Methotrexate
L04AX03activeUS GB CA AU SG CN ES MX TW EUdiscontinuedCA ES MXwithdrawnES MXunknownAU MX HK - Lenalidomide
L04AX04Salt form: Lenalidomide Hydrochloride MonohydrateactiveUS GB CA AU SG CN ES MX TW EUdiscontinuedCA ESwithdrawnES EUunknownAU MX HK - Tacrolimus
L04AD02Salt form: Tacrolimus MonohydrateactiveUS GB CA AU SG CN ES MX TW EUdiscontinuedCA ES MXwithdrawnES MX EUunknownAU MX HK - Leflunomide
L04AK01activeUS GB CA AU SG CN ES TW EUdiscontinuedCA ES MXwithdrawnES EUunknownAU HK EU - Pomalidomide
L04AX06activeUS GB CA AU SG CN ES MX TW EUdiscontinuedCA ES MXunknownAU HK - Azathioprine
L04AX01activeUS GB CA AU SG CN ES MX TW EUdiscontinuedCA MXwithdrawnES MXunknownAU HK - Tofacitinib
L04AA29L04AF01Salt form: Tofacitinib CitrateactiveUS GB CA AU SG CN ES MX TW EUdiscontinuedCA ES MXunknownAU MX HK EU - Pirfenidone
L04AX05activeUS GB CA AU SG CN ES TW EUdiscontinuedCA ES MXwithdrawnESunknownAU MX HK - Fingolimod
L04AA27L04AE01Salt form: Fingolimod HydrochlorideactiveUS GB CA AU SG CN ES MX TW EUdiscontinuedCA ESwithdrawnESunknownAU HK - Teriflunomide
L04AK02activeUS GB CA AU SG CN ES MX TW EUdiscontinuedCA ESwithdrawnESunknownAU MX HK - Sirolimus
L04AH01activeUS GB CA AU SG CN ES TW EUdiscontinuedCA ES MXwithdrawnMXunknownAU MX HK - Golimumab
L04AB06activeUS GB CA AU SG CN ES MX TW EUdiscontinuedES MXunknownAU HK - Cladribine
L04AA40activeUS GB CA AU SG CN ES TW EUdiscontinuedCA ES MXunknownAU HK EU - Secukinumab
L04AC10activeUS GB CA AU SG CN ES TW EUdiscontinuedES MXunknownAU HK - Baricitinib
L04AF02activeUS GB CA AU SG CN ES TW EUdiscontinuedMXunknownAU HK - Belimumab
L04AG04activeUS GB CA SG CN ES MX TW EUdiscontinuedCAunknownAU MX HK - Ofatumumab
L04AG12activeUS GB CA AU SG CN ES MX TW EUdiscontinuedCA ESwithdrawnMX EUunknownAU HK - Ritlecitinib
L04AF08activeUS GB CA SG CN ES MX TW EUunknownAU HK - Mycophenolate Mofetil
L04AAactiveUS GB CA SG CN MX TW EUdiscontinuedCA MXwithdrawnMXunknownAU MX HK - Adalimumab
L04AB04activeUS GB CA AU SG ES MX TW EUdiscontinuedCA ESwithdrawnES EUunknownAU MX HK - Ustekinumab
L04AC05activeUS GB CA AU SG ES MX TW EUdiscontinuedES MXwithdrawnES EUunknownAU MX HK - Apremilast
L04AA32activeUS GB CA AU SG CN ES TW EUdiscontinuedCA ES MXwithdrawnESunknownAU - Tocilizumab
L04AC07activeUS GB CA AU SG ES TW EUdiscontinuedES MXunknownAU MX HK - Etanercept
L04AB01activeUS GB CA AU SG ES TW EUdiscontinuedCA MXwithdrawnMXunknownAU MX HK EU - Infliximab
L04AB02activeUS GB CA AU SG ES MX TW EUdiscontinuedCA ES MXwithdrawnES EUunknownAU HK - Guselkumab
L04AC16activeUS GB CA AU SG ES MX TW EUdiscontinuedMXunknownAU HK - Risankizumab
L04AC18activeUS GB CA AU SG ES TW EUdiscontinuedCA ES MXunknownAU HK - Upadacitinib
L04AF03activeUS GB CA AU SG ES TW EUdiscontinuedES MXunknownAU HK - Abatacept
L04AA24activeUS GB CA AU CN ES TW EUdiscontinuedCAunknownAU MX HK - Vedolizumab
L04AG05activeUS GB CA AU SG ES MX TW EUdiscontinuedES MXunknownAU HK - Natalizumab
L04AG03activeUS GB CA AU SG ES MX TW EUunknownAU HK EU - Siponimod
L04AE03activeUS GB CA AU SG ES MX TW EUdiscontinuedESunknownHK - Eculizumab
L04AJ01activeUS GB CA AU SG CN ES TW EUdiscontinuedCAunknownAU HK - Ixekizumab
L04AC13activeUS GB CA AU SG ES TW EUdiscontinuedMXunknownAU HK - Siltuximab
L04AC11activeUS GB CA AU SG CN ES TW EUunknownAU HK - Alemtuzumab
L04AG06activeUS GB CA AU SG ES MX TW EUdiscontinuedCAwithdrawnEUunknownAU MX HK - Tildrakizumab
L04AC17activeUS GB CA AU SG ES MX TW EUdiscontinuedESunknownAU HK - Basiliximab
L04AC02activeUS GB CA SG CN TW EUdiscontinuedMXunknownAU HK - Deucravacitinib
L04AF07activeUS GB CA AU SG ES MX TW EUunknownAU HK - Dimethyl
L04AX07Salt form: Dimethyl FumarateactiveUS GB CA AU SG ES TW EUdiscontinuedCA ESwithdrawnES EUunknownAU HK - Bimekizumab
L04AC21activeUS GB CA AU ES MX TW EUunknownAU HK - Certolizumab Pegol
L04AB05activeUS GB CA AU ES TW EUdiscontinuedESunknownAU MX HK EU - Ravulizumab
L04AJ02activeUS GB CA AU SG ES TW EUdiscontinuedCAunknownAU HK - Ocrelizumab
L04AG08activeUS GB CA AU SG ES MX EUdiscontinuedES MXunknownAU HK - Danicopan
L04AJ09activeUS GB CA SG ES TW EUunknownAU HK - Canakinumab
L04AC08activeUS GB CA ES TW EUdiscontinuedCAwithdrawnESunknownAU MX HK - Iptacopan
L04AJ08activeUS GB CA AU SG ES TW EUunknownAU HK - Satralizumab
L04AC19activeUS GB CA SG ES TW EUunknownAU HK - Teprotumumab
L04AG13activeUS GB CA SG TW EUdiscontinuedESunknownAU HK - Thalidomide
L04AXactiveUS GB CA AU SG CN TW EUdiscontinuedCAunknownAU - Mirikizumab
L04AC24activeUS GB CA ES MX TW EUdiscontinuedESunknownAU - Ozanimod
L04AA38L04AE02Salt form: Ozanimod HydrochlorideactiveUS GB CA AU ES TW EUunknownAU HK - Rozanolixizumab
L04AL02activeUS GB CA AU ES TW EUunknownAU HK - Spesolimab
L04AC22activeUS GB CA SG TW EUunknownAU HK - Anifrolumab
L04AG11activeUS CA AU ES MX TW EUunknownAU HK - Etrasimod
L04AE05activeUS GB CA AU SG ES EUunknownAU HK - Avacopan
L04AJ05activeUS GB CA AU SG CNwithdrawnES EUunknownAU - Belumosudil
L04AA48activeUS GB CA TW EUdiscontinuedESunknownAU HK - Remibrutinib
L04AA60activeUS GB CA TW EUdiscontinuedESunknownAU HK - Mycophenolic Acid
L04AA06activeUS GB CA ES MXdiscontinuedCA MXwithdrawnMXunknownAU MX HK - Zilucoplan
L04AJ06activeUS GB CA AU ES TW EUdiscontinuedES - Efgartigimod Alfa
L04AL01activeUS GB CA SG ES EUdiscontinuedESunknownAU - Brodalumab
L04AC12activeUS GB CA ES TW EUunknownHK - Mycophenolate
L04AAL04AA06Salt form: Mycophenolate SodiumactiveUS AU SG CN ES TWdiscontinuedESwithdrawnESunknownAU - Sarilumab
L04AC14activeUS GB CA ES EUdiscontinuedCA ESunknownHK - Pegcetacoplan
L04AJ03activeUS GB CA AU ES EUunknownAU EU - Nerandomilast
L04AA61activeUS GB CA TW EUdiscontinuedES - Anakinra
L04AC03activeUS GB CA AU ES EUunknownAU - Diroximel
L04AX09Salt form: Diroximel FumarateactiveUS GB AU ES MX EUunknownAU - Belatacept
L04AA28activeUS GB ES EUunknownAU MX - Crovalimab
L04AJ07activeUS GB CA ES TW EU - Inebilizumab
L04AG10activeUS CA ES TW EUunknownAU - Ciclosporin
L04ADactiveSG CN TW EUunknownAU - Ponesimod
L04AE04activeUS GB CA ES EU - Filgotinib
L04AF04activeGB SG ES TW EUdiscontinuedES - Nipocalimab
L04AL03activeUS GB CA EUdiscontinuedES - Ublituximab
L04AG14activeUS GB AU ES EUunknownAU - Voclosporin
L04AD03activeUS GB ES EUunknownEU - Efalizumab
L04AG02activeGBdiscontinuedCAwithdrawnEUunknownMX - Alefacept
L04AA15activeGBdiscontinuedCAunknownMX
Show all 139 (currently showing 80) Mostrar los 139 (ahora se muestran 80) 显示全部 139 个(当前显示前 80 个) 顯示全部 139 個(目前顯示前 80 個)
- Daclizumab
L04AC01activeGBdiscontinuedCAwithdrawnEU - Imlifidase
L04AA41activeGB EUunknownAU - Tolebrutinib
L04AA62activeEUdiscontinuedESunknownAU - Darvadstrocel
L04AX08activeGBwithdrawnES EU - Sutimlimab
L04AJ04activeUS ES EU - Emapalumab
L04AA39activeUSunknownEU - Talidomida
L04AX02activeESdiscontinuedES MXunknownMX - Daclizumab Beta
L04AC01discontinuedCAwithdrawnEU - Muromonab-Cd3
L04AG01activeGBdiscontinuedCA - Rilonacept
L04AC04activeUSwithdrawnEU - Vilobelimab
L04AJ10activeUS EU - 阿达木单抗
L04ABactiveCN - 咪唑立宾
L04AXactiveCN - 托珠单抗
L04ACactiveCN - 人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白
L04ABactiveCN - 富马酸二甲酯
L04AXactiveCN - 依那西普
L04ABactiveCN - 抗人T细胞兔免疫球蛋白
L04AASalt form: 抗人T细胞猪免疫球蛋白activeCN - 乌帕替尼
L04AAactiveCN - 佩索利单抗
L04ACactiveCN - 英夫利西单抗
L04ABactiveCN - 罗普司亭N01
L04AGSalt form: 替妥尤单抗N01activeCN - 乌司奴单抗
L04ACactiveCN - 古塞奇尤单抗
L04ACactiveCN - 西尼莫德
L04AAactiveCN - Espesolimab
L04AC22activeES - 泰它西普
L04AAactiveCN - 氘可来昔替尼
L04AAactiveCN - 盐酸伊普可泮
L04AJactiveCN - 伊奈利珠单抗
L04AAactiveCN - 依马利尤单抗
L04AAactiveCN - 培塞利珠单抗
L04ABactiveCN - 阿那白滞素
L04ACactiveCN - 兔抗人胸腺细胞免疫球蛋白
L04AAactiveCN - 盐酸奥扎莫德
L04AAactiveCN - 抗CD25人源化单克隆抗体
L04ACactiveCN - 艾加莫德α
L04AAactiveCN - Prodiginine
L04AXactiveCN - Antithymocyte Immunoglobulin (Rabbit)
L04AA04activeGB - Basilixmab
L04AC02activeESdiscontinuedES - Fumarato De Tegomil
L04AX10discontinuedES - Inmunoglobulina Antitimocítica De Conejo
L04AA04activeES - Lymphocyte Immunoglobulin Anti-Thymocyte Globulin
L04AA03activeCAdiscontinuedCA - 依奇珠单抗
L04ACactiveCN - 替瑞奇珠单抗
L04ACactiveCN - 赛立奇单抗
L04ACactiveCN - 比奇珠单抗
L04ACactiveCN - 维得利珠单抗
L04AAactiveCN - 布罗利尤单抗
L04ACactiveCN - 甲磺酸贝舒地尔
L04AAactiveCN - 夫那奇珠单抗
L04ACactiveCN - 萨特利珠单抗
L04ACactiveCN - 利纳西普
L04ACactiveCN - Anti-Thymocyte Globulin
L04AA04activeCA - Icotrokinra Containing Product
L04AC28discontinuedES - Imlifidasa
L04AA41activeES - Pozelimab
L04AJ11activeUS - Remestemcel-L
L04AXactiveCA - Ritlecitinib Tosylate
L04AF08
Class names are editorial translations or come from Wikipedia (CC BY-SA 4.0) / Wikidata (CC0); each ATC page lists the exact source, licence and link for every language. Only the ATC code and the WHO hierarchy are authoritative.
Notes & licences
Status badges summarise the product records held for each ingredient (active / discontinued / withdrawn / unknown), and the market codes after each badge show where that status is recorded. Only some registers publish a status column: CA, ES and MX do; AU and HK have no status column and are recorded as unknown; CN, US, GB, TW and SG records are on the register and marked active.
Class and category names are editorial or AI-assisted translations; only the ATC code and the WHO hierarchy are authoritative.
ATC codes and hierarchy reference the WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (copyright WHOCC; the index itself is not reproduced). Ingredient/strength facts come from the regulator records listed on About.